In another study, Bellmunt et al. found that use of platinum double-chemotherapy in Phase 3 CheckMate 026 of nivolumab in patients with metastatic or recurrent PD-L1-positive NSCLC did not effectively improve their OS, relative to pembrolizumab [42]. Here, CD274 is linked to non-small cell lung carcinoma.